Acute cardiac side effects after COVID-19 mRNA vaccination: a case series.
Adolescent
Adult
BNT162 Vaccine
/ adverse effects
COVID-19
/ prevention & control
Chest Pain
Female
Humans
Male
Middle Aged
Myocarditis
/ chemically induced
Pericarditis
/ chemically induced
SARS-CoV-2
/ genetics
Vaccination
/ adverse effects
Vaccines, Synthetic
/ adverse effects
Young Adult
mRNA Vaccines
/ adverse effects
COVID-19
Inflammation
Myocarditis
mRNA vaccine
Journal
European journal of medical research
ISSN: 2047-783X
Titre abrégé: Eur J Med Res
Pays: England
ID NLM: 9517857
Informations de publication
Date de publication:
02 Jun 2022
02 Jun 2022
Historique:
received:
15
02
2022
accepted:
27
04
2022
entrez:
2
6
2022
pubmed:
3
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Vaccination against SARS-CoV-2 has been the main tool to contain the pandemic. The rush development of the 3 vaccines and their expedited approval have led to inoculation of millions of patients around the world, leading to a containment of the disease. Despite continuous viral mutations and the identification of weaker variants, the severity of the infections has been mild, with many patients being either asymptomatic or recovering at home. Currently the focus has shifted from the host of organ damage related to the infection to potential side effects of the vaccine. Myocarditis has been reported as one of the potential side effects from the mRNA vaccine, affecting young healthy individuals. Up to September 30, 2021, 1.243 cases of myocarditis after vaccination with BNT162b2 Comirnaty© were registered in young adults by the Paul-Ehrlich-Institute in Germany alone. The exact pathophysiology and the risk factors for myocarditis following vaccination remain unclear. We present a case series of eight patients with cardiac symptom shortly after SARS-CoV-2 mRNA vaccination (BNT162b6, Biontech, Comirnaty© or mRNA-1237 Moderna, Spikevax©). Eight patients between 13 and 56 years of age, vaccinated with either BNT162b2 or mRNA-1273 mRNA vaccine between January and August 2021 developed cardiac side effects shortly after either their first or second dose of the vaccine. Clinical data were retrieved from the clinical information system and analyzed. To support diagnosis of myocarditis or pericarditis, cardiac magnetic resonance imaging (MRI) was performed shortly after the onset of symptoms, with further investigations in severe cases. Symptoms were defined as dyspnea, chest pain and cardiac arrhythmia as determined by electrocardiography. Eight patients (5 males and 3 females) developed cardiac symptoms compatible with myocarditis, according to the CDC criteria, shortly after SARS-CoV-2 mRNA vaccination. Three patients (2 males, 1 female) required hospitalization due to severe chest pain and elevated troponin levels. All patients recovered fully within 7 days from the symptom onset. Our data suggest that cardiac adverse events such as myocarditis or pericarditis shortly after SARS-CoV-2 mRNA vaccination are rare but possible and occur particularly in male patients.
Sections du résumé
BACKGROUND
BACKGROUND
Vaccination against SARS-CoV-2 has been the main tool to contain the pandemic. The rush development of the 3 vaccines and their expedited approval have led to inoculation of millions of patients around the world, leading to a containment of the disease. Despite continuous viral mutations and the identification of weaker variants, the severity of the infections has been mild, with many patients being either asymptomatic or recovering at home. Currently the focus has shifted from the host of organ damage related to the infection to potential side effects of the vaccine. Myocarditis has been reported as one of the potential side effects from the mRNA vaccine, affecting young healthy individuals. Up to September 30, 2021, 1.243 cases of myocarditis after vaccination with BNT162b2 Comirnaty© were registered in young adults by the Paul-Ehrlich-Institute in Germany alone. The exact pathophysiology and the risk factors for myocarditis following vaccination remain unclear. We present a case series of eight patients with cardiac symptom shortly after SARS-CoV-2 mRNA vaccination (BNT162b6, Biontech, Comirnaty© or mRNA-1237 Moderna, Spikevax©).
PATIENTS AND METHODS
METHODS
Eight patients between 13 and 56 years of age, vaccinated with either BNT162b2 or mRNA-1273 mRNA vaccine between January and August 2021 developed cardiac side effects shortly after either their first or second dose of the vaccine. Clinical data were retrieved from the clinical information system and analyzed. To support diagnosis of myocarditis or pericarditis, cardiac magnetic resonance imaging (MRI) was performed shortly after the onset of symptoms, with further investigations in severe cases. Symptoms were defined as dyspnea, chest pain and cardiac arrhythmia as determined by electrocardiography.
RESULTS
RESULTS
Eight patients (5 males and 3 females) developed cardiac symptoms compatible with myocarditis, according to the CDC criteria, shortly after SARS-CoV-2 mRNA vaccination. Three patients (2 males, 1 female) required hospitalization due to severe chest pain and elevated troponin levels. All patients recovered fully within 7 days from the symptom onset.
CONCLUSIONS
CONCLUSIONS
Our data suggest that cardiac adverse events such as myocarditis or pericarditis shortly after SARS-CoV-2 mRNA vaccination are rare but possible and occur particularly in male patients.
Identifiants
pubmed: 35655235
doi: 10.1186/s40001-022-00695-y
pii: 10.1186/s40001-022-00695-y
pmc: PMC9160507
doi:
Substances chimiques
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
J Pediatr. 2021 Nov;238:321-323
pubmed: 34166671
Circulation. 1996 Mar 1;93(5):841-2
pubmed: 8598070
Radiology. 2021 Nov;301(2):E409-E411
pubmed: 34282971
Cardiovasc Res. 2020 Aug 1;116(10):1661-1663
pubmed: 32562489
MMWR Morb Mortal Wkly Rep. 2021 Jul 09;70(27):977-982
pubmed: 34237049
Emerg Infect Dis. 2021 Oct;27(10):2595-2603
pubmed: 34314670
Radiol Med. 2020 Nov;125(11):1124-1134
pubmed: 33025305
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206
pubmed: 34185045
J Am Coll Cardiol. 2012 Feb 28;59(9):779-92
pubmed: 22361396
Eur J Case Rep Intern Med. 2021 Jun 14;8(7):002681
pubmed: 34268277
J Korean Med Sci. 2021 Aug 16;36(32):e229
pubmed: 34402228
N Engl J Med. 2021 Sep 30;385(14):1332-1334
pubmed: 34407340
JAMA Cardiol. 2021 Oct 1;6(10):1117-1118
pubmed: 34185044
Children (Basel). 2021 Jul 18;8(7):
pubmed: 34356586
Int J Cardiol. 2021 Oct 1;340:119-121
pubmed: 34416319
Monatsschr Kinderheilkd. 2021;169(10):893-894
pubmed: 34393273
J Korean Med Sci. 2021 Aug 16;36(32):e232
pubmed: 34402230
JAMA Cardiol. 2021 Oct 1;6(10):1196-1201
pubmed: 34185046
Cureus. 2021 Jun 10;13(6):e15576
pubmed: 34277198
JAMA. 2021 Nov 23;326(20):2043-2054
pubmed: 34734975
Circulation. 2021 Aug 10;144(6):506-508
pubmed: 34133884
Circulation. 2021 Aug 10;144(6):487-498
pubmed: 34133883
Clin Infect Dis. 2021 Dec 16;73(12):2257-2264
pubmed: 33515252
JAMA Cardiol. 2021 Oct 1;6(10):1115-1117
pubmed: 34185047
Circulation. 2021 Aug 10;144(6):471-484
pubmed: 34281357
Am Heart J. 1957 Jul;54(1):156-7
pubmed: 13435214
Circ Heart Fail. 2020 Nov;13(11):e007405
pubmed: 33176455
N Engl J Med. 2021 Oct 28;385(18):1718-1720
pubmed: 34496200
Vaccine. 2021 Aug 16;39(35):4925-4927
pubmed: 34312010
JAMA. 2021 Sep 28;326(12):1210-1212
pubmed: 34347001
Vaccine. 2021 Jun 29;39(29):3790-3793
pubmed: 34092429
Clin Imaging. 2021 Oct;78:247-249
pubmed: 34166884
Can J Cardiol. 2021 Oct;37(10):1629-1634
pubmed: 34375696
Nat Rev Cardiol. 2021 Mar;18(3):169-193
pubmed: 33046850
BMJ. 2021 Jun 24;373:n1635
pubmed: 34167952
Pediatrics. 2021 Nov;148(5):
pubmed: 34389692